Omni Bio Pharmaceutical Inc

Omni Bio Pharmaceutical — Equity Micro-Cap Conference (September 2009)

30 slides from Omni Bio Pharmaceutical's conference presentation, Sep 29, 2009

  1. Slide 1: Omni Bio Pharmaceutical, Inc (OTCBB:OMBP)

    Slide 1: Omni Bio Pharmaceutical, Inc (OTCBB:OMBP)

    Pharmaceutical, Inc (OTCBB:OMBP) dited Members, Inc lL Equity Micro-Cap Conference

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements. The forward-looking statements in this presentation are based on information avaiable to us as of the date any such statements are made and we

  3. Slide 3: Pioneering the Discovery, Development, and Commercialization of Alternative Therapies

    Slide 3: Pioneering the Discovery, Development, and Commercialization of Alternative Therapies

    Pioneering the Discovery, Development, and Commercialization of Alternative Therapies for Diabetes, Bacterial and Viral Disease, and Transplant Rejection

  4. Slide 4: Omni is positioned to take advantage of large markets with unmet medical needs

    Slide 4: Omni is positioned to take advantage of large markets with unmet medical needs

    Omni is positioned to take advantage of large markets which have unmet medical needs at the present time > Type 1 Diabetes-Approximately 2 million patients in the US alone, potential $5-10 billion market. Total Current Market size for Diabetes drugs and services (type 1 and 2) of $92 billion per Can

  5. Slide 5: Omni Bio's Objectives

    Slide 5: Omni Bio's Objectives

    Omni Bio’s Objectives » To develop, patent, and commercialize new indications in potentially large markets, for drugs that have received previous FDA approval for other indication(s) » By utilizing drugs with existing approvals, new indications will be able to piggy-back on the safety record of the

  6. Slide 6: Omni Bio Overview

    Slide 6: Omni Bio Overview

    Omni Bio Overview Omni Bio becamea Public Company on March 31, 2009 when it completed a reverse merger and financing for $1.87 million, provided by institutional investors Omni is the licensee of three patent portfolios from the University of Colorado related to: Patent applications for the Treatmen

  7. Slide 7: Omni is the licensee of filed patent applications owned by the University of Colorado

    Slide 7: Omni is the licensee of filed patent applications owned by the University of Colorado

    ~-Omni is the licensee of filed patent 7" applications owned by the University of Colorado ° These filed patents include the method of use for the treatment of diabetes utilizing AAT * Our strategy is to sub-license the patents to one or more producers of AAT, many of whom are major pharmaceutical c

  8. Slide 8: Management

    Slide 8: Management

    ~ Management Acting Chief Executive Officer-Charles A. Dinarello, MD (Yale) Member of the National Academy of Sciences -Listed by Institute for Scientific Information as the world’s fourth most clted scientist for 20 years fig82-2003). Numerous international awards including 2009 Crafoord Prize (Swe

  9. Slide 9: Principal Investigator at the University of Colorado, Anschutz Medical Center

    Slide 9: Principal Investigator at the University of Colorado, Anschutz Medical Center

    Principal Investigator at the University of Colorado, Anshutz Medical Center Dr. Leland Shapiro, MD , FACP Associate Professor of Medicine University of Colorado Certified by American Board of Internal Medicine University of Massachusetts School of Medicine Broadly published researcher Dr. Shapiro i

  10. Slide 10: Scientific Advisory Board

    Slide 10: Scientific Advisory Board

    ~ Scientific Advisory Board © Dr. Michael Iseman-National Jewish Hospital and Professor at the University of Colorado. Dr. Iseman isa prominent international expert on tuberculosis, particularly, and drug resistant tuberculosis. Dr. James Crapo- National Jewish Hospital and Professorat the Universit

  11. Slide 11: What is Alpha Antitrypsin (AAT)?

    Slide 11: What is Alpha Antitrypsin (AAT)?

    ——— “What is Alpha 1 Antitrypsin (AAT)? * AATisa naturally occurring human serum protein. AAT is currently EDA approved and prescribed for emphysema and chronic obstructive pulmonary disorder in AAT deficient patients. Omnis three licenses relate to new discoveries for the use of AAT in the treatmen

  12. Slide 12: Method for Treatment of Type 1 Diabetes

    Slide 12: Method for Treatment of Type 1 Diabetes

    iethod for atment of Type 1 Diabetes A previously approved trial of AAT for off-label use will potentially allow human clinical trials in Type 1 diabetes patients.

  13. Slide 13: Institutional Review Board Submission

    Slide 13: Institutional Review Board Submission

    Institutional Review Board Submission Omni Bio and a prominent research hospital are nearing initial Institutional Review Board (IRB) approval to conduct the first trial of AAT in recently diagnosed Type 1 diabetes in children and adolescents (specifically Office for Human Research Protections). An

  14. Slide 14: Type 1 Diabetes (aka Juvenile Diabetes)

    Slide 14: Type 1 Diabetes (aka Juvenile Diabetes)

    SS Type 1 Diabetes (aka Juvenile Diabetes) © ‘Type 1 Diabetes occurs when the body's immune system attacks and destroys certain cells in the panereas, The cells, called beta cells, normally produce insulin, however when beta cells are destroyed no insulin can be produced, causing the uncontrolled gl

  15. Slide 15: Basis of Type 1 Diabetes Therapy Thesis

    Slide 15: Basis of Type 1 Diabetes Therapy Thesis

    Basis of Type 1 Diabetes Therapy Thesis * Inmice, AAT protects the insulin-producing beta cells against toxic agents e AAT has been demonstrated to protect HUMAN islet cells against toxic effects of inflammatory cytokines. Inflammatory cytokines are produced in type 1 diabetes and are the cause of c

  16. Slide 16: AAT has received previous FDA approval for use in human pancreatic islet transplantation

    Slide 16: AAT has received previous FDA approval for use in human pancreatic islet transplantation

    AT has received previous FDA approval for the use of AAT in human pancreatic islet transplantation Precedent has been established for the testing of AAT in humans on off-label fields of use * Omni has submitted a proposal to the regional Institutional Review Board to approve the protocol on a propos

  17. Slide 17: Market Size

    Slide 17: Market Size

    ~ Market Size 5 proximately 2 million Type 1 Diabetics and 22 million Type 2 Diabetics have been diagnosed in the US' (if only $1,000 per patient of AAT were provided annually this could infer toa potential $24 billion market) Approximately 8% of the US population has diabetes, and if trends continu

  18. Slide 18: How Does AAT Work?

    Slide 18: How Does AAT Work?

    How Does AAT Work? Anti-Inflammatory Inhibits Enzymes such as proteinase-3 Anti-Migratory Anti-Complement Prevents maturation of antigen presentation Induces T-regulatory cells Inhibits responses to inflammatory cytokine Increases production of anti-inflammatory molecules

  19. Slide 19: Pecan Islets: Effect of cytokine stimulation and protection by AAT

    Slide 19: Pecan Islets: Effect of cytokine stimulation and protection by AAT

    Pecan Islets: Effect of cytokine stimulation and protection by AAT TLap/IENy + ILap/IFNy AAT

  20. Slide 20: Influenza

    Slide 20: Influenza

    ~ Influenza © The Influenza Pandemic of 1918 caused an estimated 20-100 million deaths Worldwide, with approximately 675,000 American deaths, a number that was approximately 10X larger than our WWI casualties ° The effect of the pandemic was so severe that the average life expectancy in the US was r

  21. Slide 21: A : Z A

    Slide 21: A : Z A

    3 A 8 8 : Z A 2

  22. Slide 22: Effect of AAT on Flu Production at Day 3 In Vitro

    Slide 22: Effect of AAT on Flu Production at Day 3 In Vitro

    Effect of AAT on Flu Production at Day 2 In Vitro Fluaiene AAT 3ne/m AAT Ing/nL. **p<0.0004, ***p<0.0001 compared to 100% i

  23. Slide 23: AAT protects cells from flu infection

    Slide 23: AAT protects cells from flu infection

    AAT protects cells from flu infection

  24. Slide 24: Survival: Mice exposed to FLU

    Slide 24: Survival: Mice exposed to FLU

    Survival: Mice exposed to FLU (statistically significant, p=0.0007) 100° Percent survival o 2 4 6 8 10 12 14 16

  25. Slide 25: Proof of Concept: AAT deficiency is a risk factor for FLU infection

    Slide 25: Proof of Concept: AAT deficiency is a risk factor for FLU infection

    Proof of Concept: AAT deficiency is a risk factor for FLU infection

  26. Slide 26: AAT Therapy for FLU

    Slide 26: AAT Therapy for FLU

    AAT Therapy for FLU Current FLU treatments are of modest efficacy. There is an unmet need. . Use as both treatment and prophylaxis Should have efficacy for all Flu types including “bird FLU’, “Swine Flu (HiN1)”, and “weaponized” FLU AAT therapy impervious to mutation-induced resistance Compatible wi

  27. Slide 27: AAT Technologies: Status

    Slide 27: AAT Technologies: Status

    AAT Technologies: Status Indication Laboratory | Animal Human | Clinical trial studiesin | studies studies cells Anthrax s + - NA FLU + + A 7 Diabetes + ry + Pending Graft rejection + + 2 Pending Tuberculosis + + > - (vB) HIV a NA * 2 += completed or in process; -= has not been completed

  28. Slide 28: Corporate Information

    Slide 28: Corporate Information

    Corporate Information Symbol: OMBP (OTCBB) Fiscal Year End: March 31 Last Trade (9.25.2009): $13.50 Balance Sheet as of June 30, 20 Amount Cash and Equivalents $1,062,058, Total Assets 17,813 Total Liabilities 7o2,621 Stockholders Equity 495162 Working Capital 405,376 Common Stock 26,795,770 Warrant

  29. Slide 29: Business Summary

    Slide 29: Business Summary

    Business Summary » Broad Intellectual Property Position In Major Markets Diabetes Influenza 3 Licenses

  30. Slide 30: Thank you for your interest

    Slide 30: Thank you for your interest

Source: SEC EDGAR · 8-K filed Sep 29, 2009

More decks from Omni Bio Pharmaceutical Inc